CN110430882A - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN110430882A
CN110430882A CN201780088500.7A CN201780088500A CN110430882A CN 110430882 A CN110430882 A CN 110430882A CN 201780088500 A CN201780088500 A CN 201780088500A CN 110430882 A CN110430882 A CN 110430882A
Authority
CN
China
Prior art keywords
compound
cancer
hepatocellular carcinoma
fxr
fxr agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780088500.7A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼奥·莫斯奇塔
耶稣·玛丽亚·巴尼亚莱斯·阿苏儿美蒂
路易斯·布罕达·费尔南德斯·德·佩罗拉
玛丽亚·耶稣·佩鲁戈里亚·蒙提尔
欧亨·埃里切·阿斯帕伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intercept Pharmaceuticals Inc
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CN110430882A publication Critical patent/CN110430882A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780088500.7A 2017-03-07 2017-09-21 治疗癌症的方法 Pending CN110430882A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762468259P 2017-03-07 2017-03-07
US62/468,259 2017-03-07
PCT/US2017/052663 WO2018164715A1 (en) 2017-03-07 2017-09-21 Methods of treating cancer

Publications (1)

Publication Number Publication Date
CN110430882A true CN110430882A (zh) 2019-11-08

Family

ID=63447943

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780088500.7A Pending CN110430882A (zh) 2017-03-07 2017-09-21 治疗癌症的方法

Country Status (9)

Country Link
EP (1) EP3592357A4 (https=)
JP (1) JP7042836B2 (https=)
KR (1) KR20190122251A (https=)
CN (1) CN110430882A (https=)
AU (1) AU2017402623A1 (https=)
CA (1) CA3055308A1 (https=)
IL (1) IL269123A (https=)
TW (1) TW201832768A (https=)
WO (1) WO2018164715A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022011037A2 (en) * 2020-07-07 2022-01-13 The General Hospital Corporation Interleukin 33 (il-33) inhibition for treatment of cancer, fibrosis and inflammation
EP4402264A4 (en) * 2021-09-16 2025-10-15 Agency Science Tech & Res MODULATION OF TJP1 EXPRESSION TO TREAT LIVER DISEASES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US20140148428A1 (en) * 2012-11-28 2014-05-29 Intercept Pharmaceuticals, Inc. Treatment of Pulmonary Disease
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US20160145295A1 (en) * 2014-11-26 2016-05-26 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080803A2 (en) * 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
PT2040713E (pt) 2006-06-27 2014-10-13 Intercept Pharmaceuticals Inc Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017180577A1 (en) 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
US20140148428A1 (en) * 2012-11-28 2014-05-29 Intercept Pharmaceuticals, Inc. Treatment of Pulmonary Disease
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US20160145295A1 (en) * 2014-11-26 2016-05-26 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIABEI WANG等: "N-myc Downstream-Regulated Gene 2 Inhibits Human Cholangiocarcinoma Progression and Is Regulated by Leukemia Inhibitory Factor/MicroRNA-181c Negative Feedback Pathway", 《HEPATOLOGY》 *

Also Published As

Publication number Publication date
CA3055308A1 (en) 2018-09-13
JP2020510009A (ja) 2020-04-02
AU2017402623A1 (en) 2019-09-26
EP3592357A1 (en) 2020-01-15
WO2018164715A1 (en) 2018-09-13
EP3592357A4 (en) 2021-01-13
IL269123A (en) 2019-11-28
KR20190122251A (ko) 2019-10-29
JP7042836B2 (ja) 2022-03-28
TW201832768A (zh) 2018-09-16

Similar Documents

Publication Publication Date Title
KR102377338B1 (ko) 암의 치료 방법
JP2019519498A5 (https=)
WO2016176208A1 (en) Compositions of obeticholic acid and methods of use
JP2022539019A (ja) Ｐｄｌ１陽性ｎｋ細胞がん処置
WO2021263180A1 (en) Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virus
CN108779111A (zh) 结合脱氧胞苷激酶的化合物
EP3411058B1 (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
JP7042836B2 (ja) 癌を処置する方法
US20180256600A1 (en) Methods of treating cancer
US20240050515A1 (en) Methods and compositions for treating cd44+ cancers
CN113271951A (zh) 使用奥贝胆酸的方法
HK40010220A (en) Methods of treating cancer
US20260102466A1 (en) ß-DEFENSIN-2 PEPTIDE FOR INHIBITING CELL GROWTH OF COLON CANCER
HK1260434A1 (en) Methods of treating cancer
US20230272103A1 (en) Cd44-modulating compositions for methods for treating cancers and ascites
CA2925305A1 (en) Combination therapy with a6 and chemotherapeutic agents for the treatment of cancer
HK40001457B (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK40001457A (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010220

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191108

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40010220

Country of ref document: HK